| Dr Mark Stephen Robertson, DO | |
|
950 29th Ave Sw, Albany, OR 97321-3415 | |
| (541) 967-0404 | |
| (541) 967-6548 |
| Full Name | Dr Mark Stephen Robertson |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 27 Years |
| Location | 950 29th Ave Sw, Albany, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487679700 | NPI | - | NPPES |
| 286847 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | DO23994 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Samaritan Pacific Community Hospital | Newport, OR | Hospital |
| Good Samaritan Regional Medical Center | Corvallis, OR | Hospital |
| Samaritan Albany General Hospital | Albany, OR | Hospital |
| Samaritan North Lincoln Hospital | Lincoln city, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mark S. Robertson, P.c. | 7012915333 | 3 |
News Archive
Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.
Centers for Medicare & Medicaid Services Administrator Marilyn Tavenner said Tuesday that fixes have been made to the federal website to improve users' experiences. She also answered questions about an exchange security breach that she said is fixed. In the meantime, the Obama administration faces growing skepticism from those in its own party on the rollout.
Figures released Friday reflect the number of participants in the health overhaul's high-risk pools as of April. Meanwhile, Modern Healthcare reports that Kansas has widened it's high-risk pool to allow child-only plans.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
› Verified 1 days ago
| Entity Name | Mark S. Robertson, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205975588 PECOS PAC ID: 7012915333 Enrollment ID: O20061121000506 |
News Archive
Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.
Centers for Medicare & Medicaid Services Administrator Marilyn Tavenner said Tuesday that fixes have been made to the federal website to improve users' experiences. She also answered questions about an exchange security breach that she said is fixed. In the meantime, the Obama administration faces growing skepticism from those in its own party on the rollout.
Figures released Friday reflect the number of participants in the health overhaul's high-risk pools as of April. Meanwhile, Modern Healthcare reports that Kansas has widened it's high-risk pool to allow child-only plans.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Stephen Robertson, DO 950 29th Ave Sw, Albany, OR 97321-3415 Ph: (541) 967-0404 | Dr Mark Stephen Robertson, DO 950 29th Ave Sw, Albany, OR 97321-3415 Ph: (541) 967-0404 |
News Archive
Trigemina, Inc. (TI), a Mountain View based startup, has begun a Phase IIa clinical trial for its lead molecule in Chronic Daily Headache (CDH) in collaboration with Dr. Egilius Spierings at MedVadis Research Corporation located outside of Boston.
Centers for Medicare & Medicaid Services Administrator Marilyn Tavenner said Tuesday that fixes have been made to the federal website to improve users' experiences. She also answered questions about an exchange security breach that she said is fixed. In the meantime, the Obama administration faces growing skepticism from those in its own party on the rollout.
Figures released Friday reflect the number of participants in the health overhaul's high-risk pools as of April. Meanwhile, Modern Healthcare reports that Kansas has widened it's high-risk pool to allow child-only plans.
Hapten Sciences, Inc., a privately held biotechnology company, announced today that it has filed an Investigational New Drug (IND) application and is now planning to initiate dosing of healthy volunteers in a first-in-human Phase 1 clinical trial of its lead product candidate, PDC-APB, a novel, first-in-class, compound in development for a new indication to prevent contact dermatitis due to exposure to poison ivy, oak, and sumac.
Sapheon Inc. has completed the first closing in its $18.5 million Series B Preferred equity offering. The Company issued 4,775,291 shares worth $8.6 million to Series B purchasers and convertible notes holders.
› Verified 1 days ago